Exicure, Inc.

XCUR Healthcare Biotechnology

Exicure, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $500,000.00, down 98.3% from fiscal 2022. In the quarter to June 2026, EPS grew 56.1% and free cash flow grew 65.4%, each against the same quarter a year earlier.

1.11 0.01 −0.89%
Market cap
$7.3M
P/E
0.0×
Fwd P/E
−0.3×
Dividend yield
—
F-score
n/a
Altman Z
−18.31
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
1.96 1.19 0.79 0.56
Net Debt/EBITDA
1.90 1.78 1.70 1.69
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.54) (0.15) (0.18) (0.14)
Book value per Share
1.10 0.62 0.33 0.15
Free Cash Flow
(3.42) (0.93) (1.14) (0.89)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates